Published on 27 May 2024 on Zacks via Yahoo Finance
Sanofi SNY announced that the FDA has accepted the supplemental biologics license application (sBLA), seeking expanded use of its multiple myeloma drug, Sarclisa (isatuximab).
The sBLA seeks approval for Sarclisa in combination with Velcade (bortezomib), Bristol-Myers’ BMY Revlimid (lenalidomide) and dexamethasone (VRd) for the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible.